KPV Protocol
C-terminal alpha-MSH fragment studied for anti-inflammatory and gut-healing research without pigmentation effects.
- Cycle
- 4–8 weeks
Evidence Level: Investigational / Theoretical
Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.
Human evidence: No controlled human trials.
Animal evidence: Rodent colitis and gut-inflammation models form the primary evidence base.
Introduction & Mechanism of Action
C-terminal alpha-MSH fragment studied for anti-inflammatory and gut-healing research without pigmentation effects.
Tripeptide fragment of alpha-MSH that retains anti-inflammatory activity while lacking the melanocortin-receptor pigmentation effects of the full hormone — studied particularly for gut-mucosal inflammation models.
Receptors/targets: Proposed non-melanocortin-receptor anti-inflammatory pathway (mechanism not fully established)
Areas of Research Interest
- Anti-inflammatory research
- Gut-healing studies
Benefits Reported in Research
- Anti-inflammatory research
- Gut-healing studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 200–500 mcg
Reported frequency: 1× daily, oral
Reported cycle duration: 4–8 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Side Effects
- Injection-site irritation (most commonly reported)
Contraindications
- Pregnancy
Drug interactions
- Not characterized — no controlled human drug-interaction studies exist
Safety
- No meaningful human safety database
Derived from alpha-MSH but studied for non-pigmentary anti-inflammatory effects; human clinical trials are limited.
Expected Results & Comparison
KPV and BPC-157 are both studied for gut-related research, but via different mechanisms — KPV as an anti-inflammatory melanocortin fragment, BPC-157 via broader tissue-repair/angiogenic signaling. Neither has strong human trial support, so choosing between them for gut research is a mechanism-fit question, not an evidence-strength one.